# Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

> **NCT05710666** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Trials Ireland** · enrollment: 11 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** trastuzumab deruxtecan (T-DXd) (IV)

## Key facts

- **NCT ID:** NCT05710666
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2025-09-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710666, "Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05710666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*